ResearchMoz

Breast Cancer Market Research Reports & Industry Analysis

Breast Cancer Market Research Reports & Industry Analysis Breast Cancer

Browse reports in Breast Cancer

Displaying 1 to 22 (of 22 records)
Pages: « Last  1   
US Market Changes in the Treatment of Advanced Breast Cancer
Sep 2012   |   By - Assessment Group
A survey with unfolding patient case scenarios was presented to 180 U.S. oncologists who manage patients with metastatic breast cancer for their open-ended responses. In each case, oncologists were asked to respond to questions concerning their choices of treatment regimens, factors that influenced their decisions, barriers to optimal patient treatment and confidence in treatment and...
$2900
Avastin (Breast Cancer) Analysis and Forecasts to 2020
Dec 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Avastin (Breast Cancer) Analysis and Forecasts to 2020 provides Avastin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer...
$2000
Taxol (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Taxol (Breast Cancer) Analysis and Forecasts to 2020 provides Taxol sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on...
$2000
Taxotere (Breast Cancer) Analysis and Forecats to 2017
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Taxotere (Breast Cancer) Analysis and Forecasts to 2017 provides Taxotere sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2017). The report also includes information on...
$2000
Femara (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Femara (Breast Cancer) Analysis and Forecasts to 2020 provides Femara sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer...
$2000
Herceptin (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Herceptin (Breast Cancer) Analysis and Forecasts to 2020 provides Herceptin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast...
$2000
Omnitarg (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Omnitarg (Breast Cancer) Analysis and Forecasts to 2020 provides Omnitarg sales estimates for US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer...
$2000
Trastuzumab-DM1 (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Trastuzumab-DM1 (Breast Cancer) Analysis and Forecasts to 2020 provides Trastuzumab-DM1 sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2016-2020). The report also includes...
$2000
Gemzar (Breast Cancer) Analysis and Forecasts to 2015
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Gemzar (Breast Cancer) Analysis and Forecasts to 2015 provides Gemzar sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2003-2015). The report also includes information on Breast...
$2000
Afinitor (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Afinitor (Breast Cancer) Analysis and Forecasts to 2020 provides Afinitor sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on...
$2000
Arimidex (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Arimidex (Breast cancer) - Analysis and Forecasts to 2020 provides Arimidex sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer...
$2000
Aromasin (Breast Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Aromasin (Breast cancer) - Analysis and Forecasts to 2020 provides Aromasin sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the estimate period (2002-2020). The report also includes information on Breast Cancer...
$2000
Faslodex (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Faslodex (Breast cancer) - Analysis and Forecasts to 2020 provides Faslodex sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the estimate period (2002-2020). The report also includes information on Breast...
$2000
Neratinib (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Neratinib (Breast cancer) - Analysis and Forecasts to 2020 provides Neratinib sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Breast Cancer...
$2000
Nolvadex (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Nolvadex (Breast cancer) - Analysis and Forecasts to 2020 provides Nolvadex sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forcast period . The report also includes information on Breast Cancer market....
$2000
Tykerb (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Tykerb (Breast cancer) - Analysis and Forecasts to 2020 provides Tykerb sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer...
$2000
Xeloda (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Xeloda (Breast cancer) - Analysis and Forecasts to 2020 provides Xeloda sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer...
$2000
Zoladex (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Zoladex (Breast cancer) - Analysis and Forecasts to 2020 provides Zoladex sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer...
$2000
Abraxane (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Abraxane (Breast cancer) - Analysis and Forecasts to 2020 provides Abraxane sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2005-2017). The report also includes information on...
$2000
Ellence (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Ellence (Breast cancer) - Analysis and Forecasts to 2020 provides Ellence sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2014). The report also includes information on...
$2000
Halaven (Breast cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Halaven (Breast cancer) - Analysis and Forecasts to 2020 provides Halaven sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2011-2020). The report also includes information on Breast Cancer...
$2000
Breast Cancer Market Report: 2011 Edition
Jun 2011   |   By - Koncept Analytics
Breast cancer is one of the most common types of cancer after lung cancer and the second leading cause of death in women. Globally, more than one million women are diagnosed with breast cancer annually. Breast cancer is mainly found in women compared to men. Though women of all ages are at risk of developing breast cancer, older woman have greater chances of developing it. The incidence rates...
$800
 
Displaying 1 to 22 (of 22 records)
Pages: « Last  1